Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Pomalidomide in Healthy Chinese Volunteers
NCT03424928Phase 1Completed
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Jan 2018
- Primary completion
- Jan 2018
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pomalidomide in multiple myeloma (MM) (2 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoints: Peak Plasma Concentration at Day 10, Area under the plasma concentration versus time curve from 0 to the last measurable concentration at Day 10 and 1 more. Started Jan 2018; status: completed.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03424928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03424928.